We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Name | Symbol | Market | Type |
|---|---|---|---|
| Roche Holdings Ltd AG (QX) | USOTC:RHHBY | OTCMarkets | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.57 | 1.95% | 29.83 | 29.78 | 29.86 | 30.08 | 29.715 | 30.04 | 4,829,456 | 21:22:28 |
From May 2019 to May 2024
By Colin Kellaher
Proteostasis Therapeutics Inc. (PTI) Monday said it agreed to license rights to potential therapeutic small molecule modulators of an undisclosed target within the proteostasis network to Roche Holdings AG's (ROG.EB) Genentech unit.
The Boston clinical-stage biopharmaceutical company said it eligible to receive more than $100 million in up-front and milestone payments, along with tiered royalties on sales of medicines resulting from the deal.
Shares of Proteostasis, which closed Friday at $4.81, rose 12.3% in premarket trading Monday.
The specific therapeutic target and disease area covered by the agreement weren't disclosed, but Proteostasis said it doesn't include cystic fibrosis transmembrane conductance regulator modulators and is unrelated to the company's work in cystic fibrosis.
The company said Genentech is responsible for all further research and development expenses related to the program.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
December 17, 2018 07:43 ET (12:43 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
1 Year Roche (QX) Chart |
1 Month Roche (QX) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
